Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Biota Pharmaceuticals Inc    NABI   US6295191091

SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Operates as an anti-infective drug development company

Biota Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of products to prevent and treat serious and potentially life-threatening infectious diseases.

The Company currently has two Phase 2 clinical-stage product candidates in development: laninamivir octanoate, a long-acting neuraminidase inhibitor that the Company is developing for the treatment of influenza A and B infections under an investigational new drug application (IND) in the United States through a contract with the U.S. Office of Biomedical Advanced Research and Development Authority (BARDA) that is designed to provide up to $231 million in financial support to complete its clinical development; and vapendavir, a potent, oral broad spectrum capsid inhibitor of enteroviruses, including human rhinovirus (HRV).

In addition to these clinical-stage programs, the Company has a preclinical program focused on developing treatments for respiratory syncytial virus (RSV).

Biota Pharmaceuticals was founded on November 8, 2012 and is headquartered in Alpharetta, GA.
Managers
NameAgeSinceTitle
Russell H. Plumb MBA, CPA542012President, CEO, CFO, Secretary & Treasurer
James Charles Fox, PhD622012Chairman
John Nicholas Lambert, PhD--Vice President-Product Development & Operations
Anna Novotney-Barry-2013Vice President-Clinical Development
Simon P. Tucker, PhD--Vice President-Research & Business Development
Geoffrey F. Cox, PhD702012Independent Non-Executive Director
Richard James Hill672012Independent Non-Executive Director
Anne M. VanLent662013Independent Non-Executive Director
Michael R. Dougherty562013Independent Non-Executive Director
John P. Richard, MBA562013Independent Non-Executive Director
Shareholders
NameShares%
East Hill Management Co. LLC 2,940,2898.38%
JPMorgan Asset Management (UK) Ltd. 2,480,9717.07%
HealthCor Management LP 1,150,0003.28%
Baker Bros. Advisors LP 1,106,9103.15%
Hunter Hall Investment Management Ltd. 1,008,9392.87%
BlackRock Advisors LLC 842,5942.40%
DAFNA Capital Management LLC 729,7812.08%
Broadfin Capital LLC 636,7001.81%
Visium Asset Management LP 600,0001.71%
BVF Partners LP 435,9001.24%
Sector
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Bio Therapeutic Drugs
Advertisement
Surperformance© rating
Overall rating
Trading Rating -
Investor Rating -
Growth (Revenue) -
Valuation -
Finances -
Profitability -
Earnings quality
Business Predictability -
PER -
Potential -
Yield -
Consensus -
7 days EPS revision -
4 months EPS revision -
1 year EPS revision -
4 months Revenue revision -
1 year Revenue revision -
More Ratings
Sector Biotechnology & Medical Research
Growth (Revenue) Profitability
ITI INC
ACTELION LTD
SHANGHAI RAAS BLO..
-
MEDIVATION INC
INTERCEPT PHARMAC..
MANNKIND CORPORAT..
NPS PHARMACEUTICA..
BEIJING SL PHARMA..
HUALAN BIOLOGICAL..
GENMAB A/S
TONGHUA DONGBAO P..
GW PHARMACEUTICAL..
MEDIGEN BIOTECHNO..
-
BIOCON LTD
KERYX BIOPHARMACE..
OPHTHOTECH CORP
AGIOS PHARMACEUTI..
DYAX CORP.
CLOVIS ONCOLOGY I..
ACORDA THERAPEUTI..
Sector Biotechnology & Medical Research
Company contact information
Biota Pharmaceuticals, Inc.
2500 Northwinds Parkway
Suite 100
Alpharetta, GA 30009

Phone : +1.678.221.3343
Web : www.biotapharma.com
© 2014 Factset   
Dynamic quotes  
ON
| OFF